QIAGEN Announces European Launch of Therascreen IDH1/2Test for Gliomas
January 06, 2014 at 16:49 PM EST
QIAGEN (NASDAQ: QGEN ) announces European launch of therascreen® IDH1/2 test for gliomas as well as a IDH1/2-related collaboration with Mayo Clinic · QIAGEN's therascreen® IDH1/2 RGQ Kit is the first CE-marked test targeting IDH1 and IDH2 biomarkers to diagnose brain gliomas and assess prognoses · Partnership with Mayo
